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مقارنة تأثريات الكليبنكالميد مع امليتفورين على 
الربوتني التفاعلي نوع )ج( وحالة األكسدة/ مضادات 
األكسدة عند مرضى السكري من النوع الثاين
عالء اأبو بكر، عماد ثانون
امللخ�ص: الهدف: تهدف هذه الدرا�سة اىل مقارنة تاأثريات امليتفورمني والكليبنكالميد على الربوتني التفاعلي عايل احل�سا�سية نوع )ج( 
الثاين حديثي  النوع  من  ال�سكري  مر�سى  عند  الدم  الكلّية( يف م�سل  الأك�سدة  ُم�سادات  وحالة  باملالونديليهايد  الأك�سدة )ممثال  و�سغط 
103 مري�سا  الدرا�سة  الطريقة: تطّوع يف هذه  ال�سابطة.  العالج باملقارنة مع املجموعة  البداية، وبعد مرور �سهرين من  الت�سخي�س يف 
م�سابا بال�سكري من النوع الثاين حديثي الت�سخي�س من مركز الوفاء للبحوث وعالج ال�سكري، للفرتة من ت�رصين الثاين/نوفمرب 2009 
الكليبنكالميد. �سّمت  دواء  )50 مري�سا(  الباقون  اأعطي  بينما  امليتفورمني،  بدواء  53 منهم  2011، مت عالج  الثاين/يناير  كانون  اإىل 
وقيا�س  امل�سول  عينات  عزل  ومت  الليل،  �سيام  بعد  امل�ساركني  من  الدم  عّينات  �ُسحبت  الأ�سحاء.  من  40متطوعا  ال�سابطة  املجموعة 
م�ستويات الربوتني التفاعلي عايل احل�سا�سية نوع )ج( ، املالونديليهايد وحالة م�سادات الأك�سدة الكلّية. بعد �سهرين من العالج الأحادي 
اإح�سائية ُمعتّدة بني املر�سى امُلعاجلني بامليتفورمني  النتائج: كانت هناك فروقا  اأعاله.  مت �سحب عينة دم ثانية واإعادة الفحو�سات 
م�سادات  وحالة  واملالونديليهايد  )ج(،  نوع  احل�سا�سية  عايل  التفاعلي  الربوتني  من  لكل  بالن�سبة  ال�سابطة  واملجموعة  والكليبنكالميد 
الك�سدة الكلّية، حيث كان هناك انخفا�سا اإح�سائيا ُمعتّدا يف م�ستوى املالونديليهايد مع ارتفاع ُمعتد من الناحية الإح�سائية يف م�ستوى 
م�سادات الأك�سدة الكلّية مع عدم وجود تاثري معتّد اإح�سائيا على م�ستوى الربوتني التفاعلي عايل احل�سا�سية نوع ج بعد امليتفورمني ولكن 
مل يكن هنالك تاثري ُمعتّد على تلك املفردات بعد الكليبنكالميد. ن�سبة الختالف يف هذه املفردات بعد العقارين اأظهرت ارتفاعا معتّدا يف 
م�ستوى م�سادات الأك�سدة الكلّية مع عالج امليتفورمني وتاأثري غري معتد على م�ستوى املالونديلهايد والربوتني التفاعلي عايل احل�سا�سية 
نوع )ج(. اخلال�صة: اأظهر امليتفورمني تاثريا اإيجابيا على املوازنة بني الك�سدة/م�سادات الك�سدة يف مر�سى ال�سكري من النوع الثاين 
حديثي الت�سخي�س مع عدم وجود تاأثري معتّد على م�ستوى الربوتني التفاعلي عايل احل�سا�سية نوع )ج(. من جهة اأخرى مل يكن للكليبنكالميد 
تاأثري معتّد على حالة املوازنة بني الأك�سدة/م�سادات الأك�سدة وم�ستوى الربوتني التفاعلي عايل احل�سا�سية نوع )ج(.
مفتاح الكلمات: مر�س ال�سكري، امليتفورمني، الكليبنكالميد، املالونديليهايد، حالة م�سادات الأك�سدة الكلّية، الربوتني التفاعلي عايل احل�سا�سية 
نوع )ج(.
abstract: Objectives: This study aimed to compare the effects of metformin and glibenclamide on high sensitivity 
serum C-reactive protein (hs-CRP) and oxidative stress, represented by serum malondialdehyde (MDA) and total 
antioxidant status (TAS) in newly-diagnosed patients with Type 2 diabetes mellitus (DM) at baseline and after 2 
months of therapy in comparison to controls. Methods: The subjects, recruited from Al-Wafaa Centre for Diabetes 
Management and Research, Iraq, November 2009 to January 2011, were 103 newly-diagnosed Type 2 DM patients; 
53 were prescribed metformin and 50 glibenclamide. The control group was 40 apparently healthy volunteers. 
Blood samples were taken from all subjects after overnight fasting. Sera were separated and assays of hs-CRP, MDA 
and TAS were done. After 2 months monotherapy, the blood samples and assays were repeated. Results: There were 
significant differences between patients prescribed metformin and glibenclamide and the controls with regard to 
serum hs-CRP, MDA and TAS. There was a significant reduction in the serum MDA and a significant raise in the 
serum TAS levels, with no significant effects on serum hs-CRP levels after metformin therapy, but no significant 
effects on these parameters after glibenclamide therapy. The percentage of variation in these parameters after both 
drugs, showed a significant raise in serum TAS levels with the metformin therapy with no significant effects in 
serum MDA and hs-CRP. Conclusion: Metformin positively affected the oxidant/antioxidant balance in newly-
diagnosed Type 2 DM patients with no significant effects on acute phase reaction protein. Glibenclamide had no 
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Type II diabetes mellitus (DM) is extremely common and increasing rapidly worldwide. The diabetes epidemic is 
driven, in part, by a parallel epidemic of obesity.1 
Inflammation has been strongly implicated in Type 
II DM.2 Long-term cytokine-mediated acute-phase 
response has been postulated to play an important 
role in the pathogenesis of Type II DM.3 Oxidative 
stress (OS) has been suggested to play an important 
role in the development and progression of diabetes 
mellitus.4,5 It has been suggested that in diabetic 
patients a major factor responsible for enhanced 
free radical generation is hyperglycaemia6 through 
auto-oxidation of glucose7 and production of 
advanced glycation end products (AGEs),8 which is 
known to progress at an extremely accelerated rate 
in Type II DM.9 
Metformin is recommended as an oral 
hypoglycemic core therapy in diabetes management 
worldwide and the guidelines of the American 
Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD) 
recommend its use in patients irrespective of age, 
body weight and degree of baseline hyperglycaemia, 
due to its favourable effect on metabolic indices 
of glucose, lipid, and weight control.10 On the 
other hand, glibenclamide is a well-known second 
generation sulfonylurea (SU) that has been the 
mainstay for treatment of patients with Type 
II DM for years.11 The aim of this study was to 
assess and compare the effects of metformin and 
glibenclamide on acute phase protein (represented 
by high sensitivity serum C-reactive protein 
[hs-CRP]) and on oxidative/antioxidant status 
(represented by serum malondialdehyde [MDA] 
and total antioxidant status [TAS]) in newly-
diagnosed patients with Type II DM at baseline and 
after 2 months of therapy. 
Methods
The study was conducted at Al-Waffaa Center of 
Diabetes Management and Research in Mosul City, 
Iraq, from November 2009 to January 2011. It was 
approved by the Regional Research Committee of 
Mosul Health Administration, A follow-up design 
was adopted for the study.
Fifty-three patients newly-diagnosed with Type 
II DM were selected and prescribed metformin 
monotherapy (Dialon, Julphar, United Arab 
Emirates). They were 23 females and 30 males with a 
mean age of 51.27±9.07 years, and a body mass index 
(BMI) of 29.18±2.86. Another 50 newly-diagnosed 
patients with Type II DM were also recruited in 
this study and were prescribed glibenclamide 
monotherapy (Glibesyn, Medochemie, Cyprus). 
They were 25 females and 25 males with a mean age 
of 49.40±7.81 years, with a mean BMI of 26±2.70.
Inclusion criteria included: newly-diagnosed 
cases of Type II DM with fasting glucose ≥7.00 
mmol/L (126 mg/dL, or 2-hour post-load glucose 
≥11.1 mmol/L [200 mg/dL]) in accordance with the 
ADA and the World Health Organization (WHO) 
diagnostic criteria for Type II DM.12,13 Patients 
excluded from this study were pregnant or lactating 
women, those requiring insulin, or a combination of 
oral hypoglycemic therapy, or those known to have 
hypertension, or cardiac, renal or hepatic disorders.
Forty apparently healthy volunteers were also 
recruited as a control group. They were 21 females 
and 19 males, with a mean age of 46.90±11.91 years 
and a mean BMI of 26.90±2.77.
The sampling was performed as follows. At 8.30 
am, 5 ml venous blood samples were taken from 
both the diabetic patients and control subjects 
after overnight fasting. Sera were separated and 
measurements of hs-CRP, MDA and TAS were 
significant effects on oxidant/antioxidant balance and acute phase reaction protein.
Keywords: Diabetes mellitus; Metformin; Glibenclamide; Malondialdehyde (MDA); Total antioxidant status (TAS); 
High sensitivity serum C-reactive protein (hs-CRP).
Advances in Knowledge
1. Type II diabetes mellitus is shown by this study to be associated with oxidative stress and metformin (an oral hypoglycaemic agent) to 
have a positive effect on oxidant/antioxidant balance.
Applications to Patient Care
1. Metformin possesses an advantage over glibenclamide with regard to the effects on oxidant/antioxidant status.
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done. After 2 months of monotherapy, repeated 
blood samples were taken and the same parameters 
measured using the same kits and the same 
analytical methods: 1) hs-CRP was measured by 
enzyme–linked immunosorbent assay (ELISA), 
using BioCheck hs-CRP ELISA kit (BioCheck Inc., 
California, USA); 2) Serum MDA was measured 
using the thiobarbituric acid (TBA) assay method;14 
3) Serum TAS was measured according to the 
method of Miller et al.15 using a kit  supplied by 
Randox Laboratories (Co. Antrim, Ireland), and 
4) BMI was calculated according to the following 
equation: BMI = weight (kg)/height (m2).16
Standard statistical methods were used to 
determine the mean and standard deviation (SD). 
The unpaired t-test was used to compare the 
results of various parameters between diabetic 
patients and controls and to between diabetic 
patients on metformin and those on glibenclamide 
monotherapy. The paired t-test was used to compare 
the results of various parameters between diabetic 
patients before and after therapy. A P value of ≤0.05 
was considered to be statistically significant.17
Results
There were significant differences between patients 
prescribed metformin [Table 1], glibenclamide 
therapy [Table 2] and the control subjects with 
regard to serum hs-CRP, MDA and TAS.
There was a significant reduction in serum 
MDA with a significant rise in the serum TAS 
levels and an insignificant effect on serum hs-
CRP after metformin therapy [Table 3]. Patients 
on glibenclamide therapy showed non-significant 
differences with regard to serum levels of MDA,TAS 
and hs-CRP [Table 4].
There was a significant rise in the serum TAS 
levels after metformin therapy compared to 
glibenclamide therapy, while no significant effects 
on serum MDA and hs-CRP levels were found 
[Table 5].
Discussion
The results of the present study showed no 
significant decrease in serum hs-CRP levels in 
newly-diagnosed patients with Type II DM after two 
months metformin therapy, and only insignificant 
differences in serum hs-CRP levels in diabetic 
patients on glibenclamide therapy. 
In regard to metformin therapy, our findings 
were in accordance with the results of previous 
studies,18-20 while the results of the glibenclamide 
therapy were in agreement with the study conducted 
by Yudkin, et al. who found that markers of acute 
phase activation measured by concentrations 
of CRP in patients with Type II DM were not 
significantly influenced by SU.21 Moreover, these 
findings were in concordance with those reported 
by Derosa et al. who reported that no variations in 
hs-CRP levels were observed in patients with Type 
II DM treated with glibenclamide.22
On the other hand, Akbar found that serum 
CRP level in well-controlled Type II DM patients 
with metabolic syndrome was significantly lower 
in patients using metformin compared with those 
using glibenclamide; he concluded that metformin 
Table 1: Comparison between patients prescribed 
metformin therapy and controls with regards to serum 
levels of high sensitivity serum C-reactive protein (hs-
CRP), malondialdehyde (MDA) and total antioxidant 
status (TAS)













Note: Comparison done using unpaired t-test.
Table 2: Comparison between patients prescribed 
glibenclamide therapy and controls with regards to 
serum levels of high sensitivity serum C-reactive 
protein (hs-CRP), malondialdehyde (MDA) and total 
antioxidant status (TAS)













Note: Comparison done using unpaired t-test.
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produces a greater decrease in the level of 
circulating CRP than glibenclamide.23 Kahn, et al. 
reported that the reduction in serum hs-CRP in 
patients recently diagnosed with Type II DM was 
greater with metformin monotherapy (26%) versus 
glyburide (10%) after 12 months of therapy.24
This study showed a significant elevation in 
serum MDA levels (P <0.001) in patients with Type 
II DM prescribed metformin therapy compared 
to their matched healthy controls. OS is proposed 
to be an early event in the pathology of DM and 
may influence the onset and progression of late 
complications.25 Furthermore, elevated levels of 
serum MDA, as a marker of OS, have been reported 
in Type II DM.26 
Conflicting data were obtained regarding the 
effects of metformin on OS in diabetic patients.27 
The present work revealed a significant decrease 
in serum MDA levels in newly-diagnosed Type 
II DM patients after a 2-month therapy with 
metformin. These results were in agreement 
with the study conducted by Pavlovic, et al. who 
reported a significant reduction in MDA levels in 
both erythrocytes and plasma in newly-diagnosed 
patients with Type II DM who had been on 
metformin therapy for a period of 4 weeks.28 These 
results were also in line with those reported by 
Tessier et al. who observed that metformin therapy 
significantly decreased serum MDA levels in adult 
patients with Type II DM after a period of treatment 
for 24 weeks.29
Conversely, Skrha et al. observed that 3-month 
therapy with metformin was accompanied by 
significantly increased plasma MDA levels in Type 
II DM patients.30 They concluded that initiation 
of metformin treatment in such patients was 
associated with activation of OS. Gupta et al., 
observed no change in MDA levels at the end of 
the 12 weeks treatment with metformin, in newly-
diagnosed Type II DM patients.31
The present study also revealed a significant 
increase (P <0.05) in TAS of newly-diagnosed Type 
II DM patients after a 2-month metformin therapy, 
which is consistent with those reported by Tessier 
et al.29 They observed that a 24-week therapy with 
metformin significantly increased serum levels 
of antioxidant vitamin E in adult patients with 
Type II DM. This is in agreement with the results 
of Pavlovic et al. who reported that metformin 
significantly increased the erythrocyte activities 
of copper, zinc, superoxide dismutase, catalase 
and glutathione (GSH) levels, and decreased 
erythrocyte susceptibility to OS in patients with 
Type II DM.28 In line with these studies, Skrha et 
al. observed that 3 months of metformin treatment 
Table 3: Comparison of serum levels of high sensitivity 
serum C-reactive protein (hs-CRP), malondialdehyde 
(MDA) and total antioxidant status (TAS) for patients 
before and after metformin therapy

















NS = Not significant using paired t-test
Table 5: Percentage of variations in measured 
parameters after metformin and glibenclamide therapy
Parameters ( % variations after therapy) 















NS = Not significant using unpaired t-test
Table 4: Comparison of serum levels of high sensitivity 
serum C-reactive protein (hs-CRP), malondialdehyde 
(MDA) and total antioxidant status (TAS) for patients 
before and after glibenclamide therapy.










4.95± 2.71 5.46± 2.76 NS
MDA
(μmol/ L)
1.76± 0.26 1.73± 0.26 NS
TAS
(mmol/ L)
1.33± 0.31 1.35± 0.26 NS
NS = Not significant using paired t-test
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was accompanied by significantly increased ascorbic 
acid concentrations and concluded that initiation 
of metformin treatment in Type II DM patients 
was associated with activation of the antioxidant 
system.30
With regards to glibenclamide therapy, this study 
showed an insignificant decrease in serum MDA 
levels in newly-diagnosed Type II DM patients 
after a 2-month therapy. These findings were in 
agreement with those reported by Stefanovic et al.32 
They reported no significant decrease in the plasma 
MDA levels of patients treated with glibenclamide 
at the end of 3 months treatment. On the other 
hand, Chugh et al. reported a significant fall in 
serum MDA levels in patients with Type II DM at 
the end of 12 weeks using glibenclamide, although 
the MDA levels were not normalised and stayed 
higher than those in controls.33 This study also 
showed an insignificant increase in TAS levels of 
newly-diagnosed Type II DM patients after therapy 
with glibenclamide. These results were in line with 
those mentioned by Jennings et al. who found no 
significant difference in red blood cell superoxide 
dismutase activity, or in plasma thiols (PSH) levels, 
in Type II DM patients with retinopathy after 3 
months of treatment with glibenclamide.34 Similarly, 
Chugh et al. reported increased levels of GSH in 
patients with Type II DM at the end of a 12-week 
glibenclamide treatment period and concluded 
that this revealed beneficial effects on OS, although 
normalisation was not achieved.33
The present study showed an insignificant 
decrease in serum MDA levels, with a significant 
increase in TAS in patients treated with metformin 
compared with those treated with glibenclamide. 
This is in line with the findings of the study 
conducted by Faure et al.35 They found that the MDA 
levels were significantly lower in metformin-treated 
Type II DM patients compared to those treated 
with SU. It is possible that the short-term treatment 
durations in our study may have influenced the 
endpoints of the present study.36
With regard to antioxidant status, our findings 
were in agreement with Faure et al.35 where there 
was a significant increase in antioxidant protection, 
as shown by TAS, total blood GSM and plasma thiols 
in patients with Type II DM receiving metformin 
compared with those receiving SU, and those 
authors concluded that a significant protection of 
serum albumin was found in patients with Type II 
DM treated with metformin, and that this leads to 
an increased antioxidant protection.
Conclusion
This study has shown that metformin therapy for 
2 months in newly-diagnosed Type II DM patients 
positively affected the oxidant/antioxidant balance 
while having insignificant effects on acute phase 
reaction protein. On the other hand, glibenclamide 
had insignificant effects on the oxidant/antioxidant 
balance and on acute phase reaction protein.
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